Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Production volumes of IT equipment and high-end smartphones exceeded expectations, increasing product demand. In nucleic acid contract manufacturing, large-scale disease-related projects moved from the clinical stage to the commercialization stage, improving profitability. This was partly offset by the appreciation of the yen, which reduced operating profit by ¥8.1 billion.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥1,028,171 million (YoY +1.4%) |
| Operating profit | ¥183,615 million (YoY -1.1%) |
| Ordinary income | ¥184,976 million (YoY -0.2%) |
| Profit attributable to owners of the parent | ¥133,498 million (YoY -2.7%) |
| Net income per share | ¥197.20 |
| Operating Margin | Current fiscal year 17.9 % / Previous period 18.3 % |
| Equity ratio | End of the current fiscal period 79.6 % / End of previous period 79 % |
| Total assets | ¥1,441,757 million |
| Net assets | ¥1,149,103 million |
| Cash flows from operating activities | ¥192,183 million |
| Cash flows from investing activities | ¥-107,436 million |
| Cash flows from financing activities | ¥-106,597 million |
| Cash and cash equivalents at end of period | ¥359,805 million |
| Full-year earnings forecast | Net Sales ¥1,065,000 million (YoY +3.6%) / Operating profit ¥193,000 million (YoY +5.1%) / Ordinary income ¥193,000 million (YoY +4.3%) / Net income ¥141,000 million (YoY +5.6%) |
| Annual Dividend Forecast | ¥60 per share → ¥64 per share（+6.7%） |
| Payout ratio | Current fiscal year 30.4 % / Next-year forecast 30.6 % |
| Shareholder Return Policy | Target a dividend on equity (DOE) of at least 4% and a total payout ratio of at least 60%. |
| Segment revenue | Industrial Tape ¥366,607 million (YoY +4.2%), Optoronics ¥527,812 million (YoY -2.6%), Human Life ¥143,702 million (YoY +8.5%) |
| Segment profit | Industrial Tape ¥51,662 million (YoY +12.6%), Optoronics ¥149,871 million (YoY -13.4%), Human Life ¥-5,041 million |
| Regional sales | ¥172,839 million, ¥96,929 million, ¥96,494 million, ¥661,908 million |
| Depreciation and amortization | ¥70,677 million |
| Impairment loss | ¥4,717 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For securities analysts and institutional investors |
| Issued Shares at Period-End | 678,659,700 Shares |
| Treasury Shares at Period-End | 4,999,950 Shares |
| Factors Behind Changes in Business Performance | Production volumes of IT equipment and high-end smartphones exceeded expectations, increasing product demand. In nucleic acid contract manufacturing, large-scale disease-related projects moved from the clinical stage to the commercialization stage, improving profitability. This was partly offset by the appreciation of the yen, which reduced operating profit by ¥8.1 billion. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Production volumes of IT equipment and high-end smartphones exceeded expectations, increasing demand for products. In addition, profitability improved as large-scale nucleic acid contract manufacturing projects moved into the commercialization stage. On the other hand, the appreciation of the yen reduced operating profit by ¥8.1 billion.